Antisense & RNAi Therapeutics Market - Global Forecast 2026-2032

The Antisense & RNAi Therapeutics Market is rapidly evolving, offering actionable opportunities for senior decision-makers. Continued technological, regulatory, and operational advances are reshaping the environment for portfolio growth and risk management in this sector.

Market Snapshot

The Antisense & RNAi Therapeutics Market grew from USD 5.46 billion in 2025 to USD 6.25 billion in 2026. It is projected to maintain a robust CAGR of 15.76%, reaching USD 15.23 billion by 2032. Growing adoption of innovative nucleic acid therapies and expanded clinical validations are fueling sustained market expansion across multiple geographies and indication categories. Dynamic partnerships, investment activity, and advances in oligonucleotide delivery are further accelerating the translation of discovery-stage assets into clinical and commercial success.

Scope & Segmentation

This report delivers detailed analysis and strategic insights across every facet of the antisense and RNA interference ecosystem, with emphasis on the following segments:

Oligonucleotide Types: Antisense oligonucleotides, interfering RNAs (including micro interfering RNAs and small interfering RNAs), with each category characterized by specific delivery, potency, and safety profiles.
Routes of Administration: Intrathecal, intravenous, subcutaneous, oral, and topical approaches, each informing patient selection, product usability, and development strategy.
Therapeutic Indications: Cardiovascular, metabolic, immunology, neurological, oncology, ophthalmology, and rare genetic disease applications, with segmentation reflecting differences in disease biology, regulatory pathways, and commercialization requirements.
End Users: Contract research organizations, pharmaceutical manufacturers, research laboratories, all influencing operational priorities and milestones across the R&D continuum.
Regional Dynamics: Americas, Europe/Middle East/Africa, and Asia-Pacific, each with distinct regulatory, clinical, and manufacturing landscapes.
Technologies: Backbone chemistry innovations, delivery platforms, conjugation strategies, and analytical methods, supporting platform differentiation and accelerated progression.

Key Takeaways

Antisense and RNA interference therapeutics enable precise targeting of disease drivers at the nucleic acid level, opening new treatment possibilities for genetically mediated, rare, and complex conditions.
Ongoing improvements in oligonucleotide chemistry and delivery platforms have reduced off-target effects and broadened the range of tissue targets, supporting expansion into new clinical indications.
Collaborative development strategies and differentiated partnership models—combining platform owners with experts in contract manufacturing and clinical execution—are central to accelerating market entry and mitigating scaling risks.
Real-world evidence and longer-lasting therapeutic effects are gaining attention among payers, shaping new models for value-based contracting and reimbursement.
Distinct regional regulatory frameworks and clinical capabilities call for tailored development, manufacturing, and market access planning to ensure successful launches globally.
Segment-level alignment between oligonucleotide types, administration strategies, and therapeutic targets helps refine portfolio construction and strategic resource allocation across development stages.

Tariff Impact on Sourcing and Operations

Tariff changes implemented in 2025 have created operational complexity for manufacturers and developers. Tariffs affecting active pharmaceutical ingredients and specialized manufacturing equipment can drive up input costs and disrupt logistics. Leading companies are responding by diversifying suppliers, nearshoring production, and seeking manufacturing efficiencies to mitigate risks. These shifts influence global development strategies, supplier selection, and clinical program planning.

Methodology & Data Sources

This analysis draws on a robust mixed-methods approach: structured interviews with senior experts spanning R&D, clinical, regulatory, and manufacturing roles; systematic literature reviews; clinical trial and patent database analysis; and comparative case studies. Quantitative datasets on manufacturing and development trends are cross-validated with public filings. Results are peer-reviewed and validated for transparency, reproducibility, and rigor.

Why This Report Matters

Enables executive teams to benchmark their pipeline and strategic positioning against a rigorously documented and segmented landscape.
Provides actionable strategies related to supply chain resilience, manufacturing scalability, and regulatory engagement for long-term leadership.
Guides resource allocation by connecting market signals, segment-level insights, and operational best practices to decision frameworks.

Conclusion

Antisense and RNAi therapeutics have reached a critical stage of maturity, linking scientific progress with operational best practices. Senior leaders who integrate deep technical expertise, supply chain agility, and strategic partnerships will be best positioned to achieve sustainable value and drive patient access in this dynamic field.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Antisense & RNAi Therapeutics Market, by Oligonucleotide Type

8.1. Antisense Oligonucleotides
8.2. Interfering RNAi
8.2.1. Micro Interfering RNAs
8.2.2. Small Interfering RNAs

9. Antisense & RNAi Therapeutics Market, by Mode Of Administration

9.1. Intrathecal
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
9.5. Topical

10. Antisense & RNAi Therapeutics Market, by Therapeutic Areas

10.1. Cardiovascular
10.2. Immunology
10.3. Metabolic Disorders
10.4. Neurological Disorders
10.5. Oncology
10.6. Ophthalmology
10.7. Rare Diseases

11. Antisense & RNAi Therapeutics Market, by End User

11.1. Contract Research Organizations
11.2. Pharmaceutical Companies
11.3. Research Laboratories

12. Antisense & RNAi Therapeutics Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Antisense & RNAi Therapeutics Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Antisense & RNAi Therapeutics Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Antisense & RNAi Therapeutics Market
16. China Antisense & RNAi Therapeutics Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Acuitas Therapeutics Inc.
17.6. Alloy Therapeutics, Inc.
17.7. Alnylam Pharmaceuticals, Inc.
17.8. Arbutus Biopharma Corporation
17.9. Arrowhead Pharmaceuticals, Inc.
17.10. AstraZeneca plc
17.11. Bayer AG
17.12. Benitec Biopharma Limited
17.13. City Therapeutics
17.14. Danaher Corporation
17.15. Eli Lilly and Company
17.16. Evox Therapeutics Ltd
17.17. GenScript Biotech Corporation
17.18. GSK PLC
17.19. Ionis Pharmaceuticals, Inc.
17.20. Merck KGaA
17.21. Novo Nordisk A/S
17.22. Pfizer Inc.
17.23. Ribocure Pharmaceuticals AB
17.24. Sanofi S.A.
17.25. Shanghai Argo Biopharmaceutical Co., Ltd.
17.26. Silence Therapeutics plc
17.27. Stoke Therapeutics, Inc.
17.28. Suzhou Ribo Life Science Co., Ltd.
17.29. Wave Life Sciences Ltd

List of Figures

FIGURE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 91. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 92. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 94. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 103. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 104. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 106. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 116. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 117. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 119. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 122. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 123. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 125. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 134. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 135. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 137. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 140. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 141. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 143. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 146. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 147. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 149. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 152. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 153. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 158. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
TABLE 159. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
TABLE 160. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
TABLE 162. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Antisense & RNAi Therapeutics market report include:

Acuitas Therapeutics Inc.
Alloy Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma Corporation
Arrowhead Pharmaceuticals, Inc.
AstraZeneca plc
Bayer AG
Benitec Biopharma Limited
City Therapeutics
Danaher Corporation
Eli Lilly and Company
Evox Therapeutics Ltd
GenScript Biotech Corporation
GSK PLC
Ionis Pharmaceuticals, Inc.
Merck KGaA
Novo Nordisk A/S
Pfizer Inc.
Ribocure Pharmaceuticals AB
Sanofi S.A.
Shanghai Argo Biopharmaceutical Co., Ltd.
Silence Therapeutics plc
Stoke Therapeutics, Inc.
Suzhou Ribo Life Science Co., Ltd.
Wave Life Sciences Ltd

Table Information

Report Attribute	Details
No. of Pages	180
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 6.25 Billion
Forecasted Market Value ( USD ) by 2032	$ 15.23 Billion
Compound Annual Growth Rate	15.7%
Regions Covered	Global
No. of Companies Mentioned	26

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot

Scope & Segmentation

Key Takeaways

Tariff Impact on Sourcing and Operations

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Antisense & RNAi Therapeutics Market Report 2025

Antisense and RNAi Therapeutics - Global Strategic Business Report

Antisense & Rnai Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

Antisense & RNAi Therapeutics Market Report by Technology, Route of Administration, Application, and Region 2025-2033

RNAi Therapeutics Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application